News

For the second quarter of 2011, the company has posted net loss of $17.3m, or $0.19 loss per diluted share, compared to $4.06m, or $0.05 loss per diluted

The companies’ decision was supported by the reevaluation of pramlintide/metreleptin program which had been in Phase 2 development as a twice-a-day injection formulation as a treatment for obesity.

Dabigatran etexilate is indicated as a preventive measure for stroke and systemic embolism in adult patients with non-valvular AF with one or more risk factors. The EC approval

Earlier, Palatin signed a research and licensing deal with AstraZeneca to develop, discover and commercialize compounds targeting melanocortin receptors to treat obesity, diabetes and related metabolic syndrome. The

The application allows users to recorde each injection, track injection sites and monitor adverse reactions. With this application, users can set up an ongoing schedule for their injections

The increased capacity of the new manufacturing facility, together with advances in ZFN design algorithms and production processes, has led to cost reductions in the development and production

The British-built range comprises a comprehensive line-up of feature-packed fridges that provide energy efficiency and reduced running costs. Lec Medical marketing executive Lucy Kinsella said the range will

The drug, which can be used in combination with insulin or other medications, helps in controlling blood sugar levels. Boston CEO David Platt said this new option in

Rhucin is under investigation as a treatment for acute attacks of angioedema for patients suffering from hereditary angioedema (HAE). The companies have received the FDA acceptance for Pharming’s